Rome

• A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta I … Recruiting
  2024-517167-23-00 5 2025-08-28 Chronic Hepatitis D Infection
• Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting
  2024-518154-16-00 5 2025-08-27 non-small cell lung cancer
• A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn’s Disease (CD) Recruiting
  2024-518914-18-00 4 2025-08-27 Moderate to Severely Active Ulcerative Colitis & Moderate to Severely
• A Phase 3, placebo-controlled study to investigate LP352 in children and adults with Developmental and Epileptic Encephalopathies Recruiting
  2024-516412-17-00 5 2025-08-26 Developmental and Epileptic Encephalopathies (DEE)
• A Phase 2a, Multi-Center, Randomized, Parallel Group, Double Blind and Placebo-controlled Clinical Trial to Assess Safety and Tolerability a … Recruiting
  2024-518563-35-00 4 2025-08-25 Alzheimer's Disease
• A clinical study of treatments for non-small cell lung cancer (MK-3475-01H) Recruiting
  2024-518761-10-00 4 2025-08-25 Non-small Cell Lung Cancer
• A clinical study of sacituzumab tirumotecan and pembrolizumab in people with endometrial cancer (MK-2870-033) Recruiting
  2024-519331-42-00 5 2025-08-22 pMMR endometrial carcinoma
• A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio … Recruiting
  2024-519525-38-00 5 2025-08-22 Heart failure
• EORTC 2022-MG: Treatment with tebentafusp or observation for patients with melanoma of the eye after surgery or radiation (ATOM Trial) Recruiting
  2023-510333-28-00 5 2025-08-20 Uveal Melanoma
• A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting
  2024-516036-94-00 9 2025-08-12 Metastatic castrate resistant prostate cancer - mCRPC
• A clinical study of V940 and pembrolizumab in people with melanoma (V940-012) Recruiting
  2024-519605-36-00 4 2025-08-08 Melanoma
• RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, TWO-ARMS, MULTICENTER, POST AUTHORIZATION EFFICACY AND SAFETY STUDY (PAES) TO CONFIRM AND COLL … Recruiting
  2024-512937-34-00 6 2025-08-06 RECURRENT LOWER RESPIRATORY TRACT INFECTIONS (RLRTIS).
• A phase IV, multicentre, open-label, single-arm study to investigate the efficacy, safety and durability of faricimab (RO6867461) in caucasi … Recruiting
  2024-515640-22-00 6 2025-08-06 polypoidal choroidal vasculopathy
• A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) Recruiting
  2024-517529-26-00 5 2025-08-04 Chronic Inflammatory Demyelinating Polyneuropathy
• Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer Recruiting
  2022-502983-19-00 4 2025-07-31 High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance
• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph … Recruiting
  2023-509630-19-00 5 2025-07-31 Esophageal Squamous Cell Carcinoma (ESCC)
• Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION) Recruiting
  2024-519521-37-01 10 2025-07-30 Acute ischemic stroke
• A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima … Recruiting
  2024-518893-15-00 5 2025-07-29 Chronic lymphotic leukemia and Small Lymphocytic lymphoma
• Efepoetin alfa for treatment of anemia in chronic kidney disease on dialysis Recruiting
  2023-503634-50-01 5 2025-07-22 Anemia in patients with chronic kidney disease on dialysis
• A study to learn about the safety and effectiveness of CRN04894 on participants Recruiting
  2024-514846-35-00 4 2025-07-22 CONGENITAL ADRENAL HYPERPLASIA
• A Study of ASTX030 (Cedazuridine in Combination with Azacitidine) in MDS, CMML, or AML Recruiting
  2024-515098-93-00 5 2025-07-22 Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML
• CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected met … Recruiting
  2024-519322-20-00 5 2025-07-21 metastatic colorectal cancer
• VyClo ITCC-092 Recruiting
  2023-508050-26-00 3 2025-07-17 AML
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting
  2024-515884-69-00 5 2025-07-16 Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Showing 625–648 of 2,096 trials